MARKET

TRVN

TRVN

Trevena Inc
NASDAQ
0.5709
-0.0101
-1.74%
After Hours: 0.5801 +0.0092 +1.61% 18:00 03/01 EST
OPEN
0.5632
PREV CLOSE
0.5810
HIGH
0.6169
LOW
0.5600
VOLUME
129.97K
TURNOVER
0
52 WEEK HIGH
3.280
52 WEEK LOW
0.5084
MARKET CAP
10.46M
P/E (TTM)
-0.1950
1D
5D
1M
3M
1Y
5Y
Trevena Granted US Patent 11,912,693 Titled 'Compounds For Modulating S1P1 Activity And Methods Of Using The Same'
Benzinga · 4d ago
Trevena Has Been Granted U.S. Patent 11,912,713 Titled "7-membered Aza-Heterocyclic Containing Delta-Opioid Receptor Modulating Compounds, Methods Of Using And Making (For Treating Pain, Migraines, Depression, Parkinsons Disease, And Other Disorders)
Benzinga · 4d ago
Weekly Report: what happened at TRVN last week (0219-0223)?
Weekly Report · 6d ago
Weekly Report: what happened at TRVN last week (0212-0216)?
Weekly Report · 02/19 10:26
Weekly Report: what happened at TRVN last week (0205-0209)?
Weekly Report · 02/12 10:20
Weekly Report: what happened at TRVN last week (0129-0202)?
Weekly Report · 02/05 10:24
Trevena Inc Elevates Barry Shin to Executive VP and CFO
TipRanks · 02/02 09:12
Weekly Report: what happened at TRVN last week (0122-0126)?
Weekly Report · 01/29 10:18
More
About TRVN
Trevena, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. It is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.

Webull offers Trevena Inc stock information, including NASDAQ: TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.